Navigation Links
International Isotopes Inc. Announces the Completion of an Agreement in Principle With Idaho State University for the Production of Copper-67 for Experimental Use in Cancer Treatment
Date:11/8/2011

IDAHO FALLS, Idaho, Nov. 8, 2011 /PRNewswire/ -- International Isotopes Inc. (OTC Bulletin Board: INIS), a leading manufacturer of nuclear medicine products, is pleased to announce it has completed an agreement in principle with Idaho State University to jointly develop processes for the production of Copper-67.  Copper-67 has shown exceptional potential in the treatment of non-Hodgkin's Lymphoma as well as bladder, colorectal, and ovarian cancers.  However, it is a difficult isotope to produce and has not been consistently made available in the U.S.  This has restricted its evaluation in cancer research and clinical trials.

Idaho State University (ISU) has developed what is believed to be a technologically advanced method for producing the isotope using technologies housed in the Idaho Accelerator Center.  Under the terms of the anticipated definitive agreement, ISU will produce the raw isotope at their accelerator center and International Isotopes will transfer the material to its facility where it will be processed and packaged in its final form.   In addition to its work at the accelerator center, ISU is providing the expertise for chemical processing.  International Isotopes will make an in- kind contribution of equipment for the isotope processing, technical support for packaging and shipping, and supporting safety staff. The International Isotopes' facility is specifically licensed by the Nuclear Regulatory Commission for this type of activity and its facility is also registered with the U.S. Food and Drug Administration as a manufacturing facility for drug products – a classification that will help facilitate the commercial development of the Copper-67 product.  The parties expect to have definitive agreements executed within the coming weeks and plan to begin work later this month.    

Steve T. Laflin, President and CEO of INIS stated, "We are very pleased to have the opportunity to work so closely with Idaho State University on the development of this important isotope.  Copper-67 has shown great promise in the treatment of several cancers and making this isotope readily and reliably available in the U.S. should help provide an additional important weapon in our nation's fight against cancer.  In addition to the positive health aspects of this isotope, I think it is especially noteworthy that we have been able to join the resources of an Idaho business and an Idaho university to proactively collaborate on the production of this potentially important medical isotope."

Dr. Arthur C. Vailas, President of ISU stated, "The agreement in principle with International Isotopes is another example of how ISU is leading the way in developing translational, cutting-edge research in the areas of health and nuclear research.  The partnership with International Isotopes will provide exciting new, potentially beneficial treatment for those afflicted with various types of cancers.  To be able to play a role in treating these diseases is exciting and speaks to the University's role as a distinguished research university leading in opportunity and innovation through research, education and service."

About Idaho State University

Idaho State University is the state's designated lead institution in health professions and medical education.

About International Isotopes Inc.

International Isotopes Inc. manufactures a full range of nuclear medicine calibration and reference standards, high purity fluoride gases, and a variety of cobalt-60 products such as teletherapy sources.  The Company also provides a wide selection of radioisotopes and radiochemicals for medical devices, calibration, clinical research, life sciences, and industrial applications and provides a host of analytical, measurement, recycling, and processing services on a contract basis to clients. The Company is in the licensing and design phase of its planned environmentally friendly, green technology, uranium de-conversion and fluorine extraction processing facility located near Hobbs, New Mexico.

International Isotopes Inc. Safe Harbor Statement

Certain statements in this press release are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements with respect to the future promise of copper-67 in the treatment of cancer, changes to the national availability of the isotope, and the ultimate accomplishments of the collaboration with ISU.  Information contained in such forward-looking statements is based on current expectations and is subject to change.  These statements involve a number of risks, uncertainties, and other factors that could cause actual results, performance or achievements of International Isotopes, Inc. to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements.  Other factors, which could materially affect such forward-looking statements, can be found in International Isotopes, Inc.'s filings with the Securities and Exchange Commission at www.sec.gov, including our annual report on Form 10-K for the year ending December 31, 2010.  Investors, potential investors and other readers are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements.  The forward-looking statements made herein are only made as of the date of this press release and International Isotopes, Inc. undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

FOR MORE INFORMATION CONTACT:

Jim Drewitz
Creative Options Communications
Investor and Public Relations
jim@jdcreativeoptions.com
Phone:  830-669-2466
www.jdcreativeoptions.com

For more information, please visit the Company web site:  www.intisoid.com


'/>"/>
SOURCE International Isotopes Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. International Experts Outline Public Health Initiatives for Future Dengue Vaccine Introduction and Control of Dengue Fever
2. Psychemedics Awarded ISO/IEC 17025 International Accreditation
3. UC San Diego Clinical Trials for Latin America International Seminar at Hospital Angeles in Tijuana
4. PAREXEL International to Present at Lazard Capital Markets Healthcare Conference and Citi Small/Mid Cap Conference
5. Dyadic International Reports 2011 Third Quarter Financial Results
6. Mettler-Toledo International Inc. Reports Third Quarter 2011 Results
7. Ellman International Introduces the New Ellumine Laser at the American Society for Dermatologic Surgery (ASDS) 2011 Annual Meeting
8. Telik Announces Ezatiostat (Telintra®) Preclinical Presentation at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
9. HeartWare International Announces Planned Departure of Chief Financial Officer
10. HeartWare International Reports Third Quarter 2011 Revenues of $21.3 Million; 54% Increase From $13.8 Million in Third Quarter 2010
11. Mettler-Toledo International Inc. to Host Third-Quarter 2011 Earnings Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/6/2017)... N.Y. , Sept. 6, 2017   PDI , ... announced it will host an educational session focused on ... bloodstream infection (CLABSI) prevention at the 2017 Annual Scientific ... which will take place at the Phoenix ... from Sept. 16-19, will also feature PDI,s ...
(Date:9/5/2017)... N.J. , Sept. 5, 2017  Getinge, ... has created a vibrant charitable donation program -- ... and support congenital heart defect research by The ... providers and the general public are encouraged to ... and submit the completed artwork to the gallery ...
(Date:9/1/2017)... 1, 2017  Bayer will present the latest research from ... Medical Oncology (ESMO) 2017 Congress, September 8-12 in ... preclinical and clinical data on Bayer,s marketed portfolio and late-stage ... "We value the ... cancer research at ESMO," said Carsten Brunn , Head ...
Breaking Medicine Technology:
(Date:9/20/2017)... Texas (PRWEB) , ... September 20, 2017 , ... ... in the Orthodontics and Clear Aligner clinical and commercial support services market) has ... of Dentistry (PGSD) in Sydney, Australia. , The PGSD is the first ...
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... In just ... Brain Booster has already been receiving positive feedback from customers trying the product for ... , Daily Brain Booster was developed by neurosurgeon Shawn Moore, MD, for everyone ...
(Date:9/20/2017)... , ... September 20, 2017 , ... ... of older Americans at risk of price gouging for their prescription drugs, according ... (TSCL) . “Because Medicare isn’t negotiating on our behalf, there’s no consistency in ...
(Date:9/20/2017)... ... , ... “RECYCLED Ezekiel's Plan for Freedom from ADDICTION”: A ... is the creation of published author, Bill Miller. Bill Miller has a ... more than a decade of addiction to prescription drugs. He has a ...
(Date:9/20/2017)... , ... September 20, 2017 , ... “Psalms of Humidity”: ... peace of mind and move the readers one step closer to God. “Psalms of ... realized that his mistakes that have been made within his life are the very ...
Breaking Medicine News(10 mins):